Teva Pharmaceutical Industries, Ltd.: Pain trials
The registry lists 11 Pain studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 3Phase 2 2Phase 3 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following BunionectomyCompletedNCT02487108Phase 3Results posted
- Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough PainTerminatedNCT00387010Phase 3Results posted
- A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release TabletCompletedNCT01769677Phase 1
- A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release TabletCompletedNCT01758978Phase 1
- Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and TolerabilityCompletedNCT01400854
- Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk HerniationCompletedNCT01240876Phase 1/2
- Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic PainCompletedNCT00343733Phase 3
- Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainCompletedNCT00236093Phase 2
- Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough PainCompletedNCT00228605Phase 3
- OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105937Phase 3
- Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105287Phase 3